Obesity and Insulin Resistance: An Ongoing Saga by Kim, Sun H. & Reaven, Gerald
Obesity and Insulin Resistance: An Ongoing Saga
Sun H. Kim and Gerald Reaven
A
lthough the adverse effects of excess adiposity
on insulin-mediated glucose uptake (IMGU) are
well-recognized (1,2), the mechanism and/or
mechanisms that explain this relationship con-
tinue to be debated. The article by Kursawe et al. (3) in this
issue of Diabetes provides another, and potentially impor-
tant, mechanism linking excess adiposity and IMGU. How-
ever, to put their ﬁndings into perspective, it might be
helpful to provide a brief history of other approaches to
this issue.
The experimental methods utilized in earlier mechanis-
tic studies are reminiscent of the study by Kursawe et al.
(3) and led to the view that metabolic abnormalities
associated with obesity were related to changes in fat cell
size rather than number (4–7). For example, ex vivo
studies on adipose tissue isolated from obese humans
demonstrated that the larger the fat cell, the more dimin-
ished the response to insulin (4). Furthermore, insulin
sensitivity of isolated fat improved following weight loss-
associated decreases in fat cell size. Although these data
indicated that differences in fat cell size affected insulin
action, the fat cell is not a major consumer of glucose (8).
Thus, these data do not necessarily explain why large fat
cells would have an adverse effect on whole-body IMGU.
Furthermore, why some individuals had large fat cells and
others did not remained unanswered.
Another approach to understanding the link between
obesity and insulin resistance (IR) has focused on differ-
ences in regional fat distribution. In particular, it has been
argued that abdominal obesity, speciﬁcally an increase in
visceral fat volume, is the fundamental culprit responsible
for IR and associated abnormalities. Mechanistically, it has
been proposed that enlarged visceral fat cells secrete a
number of inﬂammatory cytokines that lead to IR (9–11).
In this manner, fat cell enlargement and the fat cell as a
source of circulating inﬂammatory markers have merged
to create one theory accounting for the link between
obesity and IR (12,13).
The fact that IR and its associated abnormalities are
increased in obese individuals does not necessarily mean
that all obese individuals are insulin resistant (14).
McLaughlin et al. (15) have published studies using tech-
niques very similar to those of Kursawe et al. (3), attempt-
ing to identify why equally obese adults can differ
approximately threefold in terms of IMGU (14). They
found a bimodal distribution of fat cell size in isolated
subcutaneous fat with a higher proportion of small cells to
large cells in insulin resistant—as compared with insulin
sensitive—individuals. Parenthetically, McLaughlin et al.
did not ﬁnd a difference in the diameter of large cells
between these two groups. These ﬁndings, along with a
lower gene–expression proﬁle for adipose cell differenti-
ation, led these authors to suggest that insulin resistant,
obese individuals were less able to store excess fat in
newly differentiated subcutaneous fat cells, leading to its
deposition as ectopic fat in other organs and contributing
to IR.
Kursawe et al. expand on this hypothesis and propose
a comprehensive mechanism for obesity-associated IR.
They suggest that impaired adipose differentiation and
lipogenesis decrease fat storage capacity in the subcu-
taneous adipose tissue, necessitating displacement of
fat to organs such as the liver and muscle. This ectopic
fat deposition then leads to organ dysfunction and IR.
To evaluate this hypothesis, they divided obese adoles-
cents into two groups based on their relative proportion
of visceral to subcutaneous fat and found that those
with higher visceral fat were more insulin resistant, had
a higher fraction of small to large cells, and lower
gene-expression markers for adipogenesis and lipogen-
esis. They also found that the diameters of the large fat
cells were greater in those with higher visceral fat,
similar to reports of older studies. The authors inter-
preted these ﬁndings to represent a reduced capacity for
fat storage in the small cells and resultant hypertrophy
of the large cells.
While Kursawe et al. show signiﬁcant differences in fat
cell characteristics between obese adolescents with high
and low visceral fat proportion, it is not clear that their
ﬁndings lead to obesity-associated IR. For example, al-
though increased peripheral fat and ectopic fat deposition
are stated to be important for the pathogenesis of IR,
triglyceride and free fatty acid concentrations and in-
tramyocellular lipid content were not different between
the two groups. Therefore, it is not clear what accounts
for the differences in insulin sensitivity between them.
Another paradox is the disparity in racial distribution
between the high and low visceral fat groups. Only 22% of
the high visceral fat group was comprised of African
American adolescents compared with 50% in the low
visceral fat group. It is well known that visceral fat
proportion is lower in African Americans (16,17); how-
ever, as a group they may be more insulin resistant (18,19).
Not only is this contrary to the model by Kursawe et al.,
but racial effects must be considered in interpreting their
ﬁndings. Finally, the authors found evidence of cell hyper-
trophy in the high visceral fat group compared with the
low visceral fat group, whereas McLaughlin et al. did not
ﬁnd this distinction between their groups based on insulin
sensitivity (15). Whether this disparity reﬂects differences
between adolescents and adults or some other difference
based on grouping needs further evaluation.
Overall, Kursawe et al. introduce another potential link
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hypotheses (Fig. 1). However, as with previous models,
this one is not complete and raises additional questions.
Most important, perhaps, is why the capacity for fat
storage varies among equally obese individuals. In addi-
tion, as the study by Kursawe et al. is a cross-sectional
evaluation, it remains unclear the relative role of small
versus large cells or ectopic fat deposition in the initiation
of events leading to IR. Thus, the primary role of visceral
fat remains uncertain, and the book is not closed on the
ongoing story between obesity and IR. Finally, it must be
remembered that IR is not limited to obese individuals and
can be demonstrated in nonobese persons without an
increase in intraabdominal fat or circulating markers of
inﬂammation (20).
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FIG. 1. Potential links between obesity and IR.
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